Sialorrhea is frequent and invalidating in patients with amyotrophic lateral sclerosis (ALS) or Parkinson's disease (PD). Botulinum toxin (BTX) emerged as an alternative to traditional treatments. We evaluated efficacy and tolerability of ultrasound-guided BTX-B injections in parotids and submandibular glands in 18 patients with ALS or PD. At 1 week, both objective (cotton rolls weight) and subjective evaluations (dedicated clinical scales) documented sialorrhea reduction (p<0.01). ALS patients reported shorter benefit duration (p<0.001) and higher prevalence of viscous saliva (seven vs one patients), possibly due to different pattern of autonomic involvement. BTX-B seems efficacious in reducing sialorrhea in ALS and PD but the risk-benefit ratio might differ between these two conditions. This might have implications for clinical practice.

Contarino, M. F., Pompili, M., Tittoto, P., Vanacore, N., Sabatelli, M., Cedrone, A., Rapaccini, G. L., Gasbarrini, G. B., Tonali, P. A., Bentivoglio, A. R., Botulinum toxin-B ultrasound-guided injections for sialorrhea in amytrophic lateral sclerosis and Parkinson's disease, <<PARKINSONISM & RELATED DISORDERS>>, N/A; (13): 299-303 [http://hdl.handle.net/10807/14232]

Botulinum toxin-B ultrasound-guided injections for sialorrhea in amytrophic lateral sclerosis and Parkinson's disease

Contarino;Maria Fiorella; Pompili;Maurizio; Tittoto;Nicola; Sabatelli;Augusto; Rapaccini;Gian Ludovico; Gasbarrini;Giovanni Battista; Tonali;Pietro Attilio; Bentivoglio
2007

Abstract

Sialorrhea is frequent and invalidating in patients with amyotrophic lateral sclerosis (ALS) or Parkinson's disease (PD). Botulinum toxin (BTX) emerged as an alternative to traditional treatments. We evaluated efficacy and tolerability of ultrasound-guided BTX-B injections in parotids and submandibular glands in 18 patients with ALS or PD. At 1 week, both objective (cotton rolls weight) and subjective evaluations (dedicated clinical scales) documented sialorrhea reduction (p<0.01). ALS patients reported shorter benefit duration (p<0.001) and higher prevalence of viscous saliva (seven vs one patients), possibly due to different pattern of autonomic involvement. BTX-B seems efficacious in reducing sialorrhea in ALS and PD but the risk-benefit ratio might differ between these two conditions. This might have implications for clinical practice.
Inglese
Contarino, M. F., Pompili, M., Tittoto, P., Vanacore, N., Sabatelli, M., Cedrone, A., Rapaccini, G. L., Gasbarrini, G. B., Tonali, P. A., Bentivoglio, A. R., Botulinum toxin-B ultrasound-guided injections for sialorrhea in amytrophic lateral sclerosis and Parkinson's disease, <<PARKINSONISM & RELATED DISORDERS>>, N/A; (13): 299-303 [http://hdl.handle.net/10807/14232]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/14232
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact